Phospho-CD19 (Y531) Antibody

What is the functional significance of CD19 Y531 phosphorylation in B cell signaling?

CD19 Y531 phosphorylation serves as a critical regulatory mark that bridges CD19 to phosphoinositide 3-kinase (PI3K) and Src family tyrosine kinases to enable downstream activation of these pathways . This phosphorylation event is essential for:

• Decreasing the threshold for B cell activation in response to antigens

• Mobilizing intracellular Ca²⁺ stores as part of BCR signal transduction

• Enabling normal B cell differentiation and proliferation after antigen challenges

• Maintaining normal serum immunoglobulin levels and high-affinity antibody production

Functionally, CD19 acts as a signal-amplifying coreceptor for the B cell receptor (BCR), and the Y531 phosphorylation is specifically required for PI3K recruitment and activation . Experimental studies have confirmed that after BCR crosslinking, Y531 becomes rapidly phosphorylated within 2 minutes, indicating its early role in the signaling cascade .

CD19 Y531 phosphorylation occurs in multiple activation contexts beyond classical BCR stimulation:

• BCR engagement: Rapid phosphorylation occurs within 2 minutes of receptor crosslinking

• TLR9 stimulation: CpG induces CD19 Y531 phosphorylation independently of BCR crosslinking

• Tonic signaling: Basal phosphorylation is detectable in IGHV-unmutated chronic lymphocytic leukemia (CLL) cells

• Chemokine stimulation: CCR7 engagement can converge with pathways involving CD19 phosphorylation

Experimental evidence from primary human B cells demonstrates that both anti-BCR and CpG (TLR9 ligand) induce comparable CD19 phosphorylation at Y531, suggesting convergent signaling pathways between innate and adaptive immune receptors . This dual activation mechanism may explain how CD19 integrates multiple signals to fine-tune B cell responses.

How can researchers study spatial-temporal dynamics of CD19 Y531 phosphorylation?

Advanced techniques for tracking spatial-temporal dynamics of CD19 Y531 phosphorylation include:

Proximity labeling approach using CD19-APEX2 fusion proteins:

• CRISPR/Cas9 genome editing can be used to insert APEX2 at the C-terminus of CD19 at the endogenous locus

• This approach allows time-resolved analysis of CD19 interactions after BCR stimulation

• In published studies, researchers tracked CD19 interactions at eight timepoints after BCR stimulation (10 seconds to 2 hours)

• The proximity labeling reaction requires biotin phenol and hydrogen peroxide addition to cells

• After streptavidin affinity purification and MS³ analysis, over 2,800 proteins and 1,394 phosphosites can be tracked

Important considerations for implementing this approach:

• The APEX2 fusion must not interfere with CD19 trafficking or function

• Control experiments should verify that the fusion protein reaches the cell surface normally (using CD81 co-transfection trafficking assays)

• Data normalization to CD19 enrichment at each timepoint is critical for accurate interpretation

• Reference samples without biotin phenol or peroxide addition should be included to assess non-specific labeling

What molecular mechanisms connect CD19 Y531 phosphorylation to downstream effector activation?

Phosphorylation of Y531 initiates a complex signaling cascade through several interconnected mechanisms:

• Direct recruitment of signaling molecules:

  • Phosphorylated Y531 creates a binding site for PI3K

  • This interaction bridges CD19 to PI3K and Src family kinases

  • The PI3K recruitment leads to PIP3 generation and subsequent AKT activation

• Coordination with other phosphorylation events:

  • Y531 phosphorylation occurs in concert with Syk Y525/526 phosphorylation

  • While Syk protein abundance near CD19 doesn't increase upon BCR stimulation, its Y525/526 phosphorylation increases rapidly (10 seconds to 2 minutes)

  • This leads to phosphorylation of BLNK Y119, creating a scaffold for downstream complexes

• Integration with adaptor proteins:

  • The spatiotemporal coordination involves IFITM3, which functions as a PIP3-scaffold

  • CD19-Y531 phosphorylation is required for this PI3K-activation mechanism

  • ZAP-70 can augment tonic BCR signaling in certain B cell malignancies

These mechanisms demonstrate how CD19 Y531 phosphorylation serves as a central node in integrating multiple signaling inputs and outputs within the B cell signaling network.

How does CD19 Y531 phosphorylation contribute to B cell malignancies and immunodeficiencies?

CD19 Y531 phosphorylation has significant implications in both malignant transformation and immunodeficiency disorders:

B cell malignancies:

• In chronic lymphocytic leukemia (CLL), CD19 Y531 phosphorylation contributes to constitutive activation of downstream pathways

• ZAP-70 expression in CLL cases correlates with unmutated IGHV genes and converges a tonic BCR signal involving CD19 phosphorylation

• This tonic signaling provides survival and proliferation advantages to malignant B cells

Immunodeficiency disorders:

• Bi-allelic CD19 gene mutations cause common variable immunodeficiency (CVID)

• These mutations can result in truncated CD19 products where Y531 is deleted

• Patients with CD19 deficiency show impaired responses to both BCR and TLR9 stimulation

• The loss of Y531 phosphorylation prevents proper PI3K recruitment and activation, compromising B cell functions

Experimental approaches to study these conditions include:

• Comparing CD19 Y531 phosphorylation levels between normal and malignant B cells

• Analyzing signaling pathway activation in CD19-deficient patient cells

• Using gene editing to introduce patient-specific CD19 mutations and assess Y531 phosphorylation

What technical considerations are critical when validating phospho-CD19 (Y531) antibodies?

Rigorous validation of phospho-CD19 (Y531) antibodies is essential for reliable research results:

Essential controls for antibody validation:

• Specificity controls:

  • Use CD19-deficient cells as negative controls

  • Compare phosphorylated vs. dephosphorylated samples (via phosphatase treatment)

  • Test antibody recognition of phosphorylated synthetic peptides vs. non-phosphorylated peptides

• Functional validation:

  • Verify detection of increased phosphorylation after BCR stimulation (2-minute timepoint is optimal)

  • Compare results using multiple phospho-CD19 antibodies from different vendors

  • Confirm results using alternative detection methods (e.g., mass spectrometry)

• Technical considerations for immunoblotting:

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Use fresh samples when possible, as freeze-thaw cycles can reduce phosphorylation signals

  • Optimize primary antibody concentration (typically 1:1000 dilution)

  • Select appropriate blocking buffers to minimize background without masking epitopes

How can researchers integrate phospho-CD19 (Y531) data with broader B cell signalosome analysis?

Comprehensive analysis of CD19 Y531 phosphorylation within the broader B cell signaling network requires integrative approaches:

• Multi-parameter phosphoflow cytometry:

  • Simultaneously measure CD19 Y531 phosphorylation alongside other key phosphorylation sites (e.g., Syk Y525/526, BLNK Y119)

  • Correlate CD19 phosphorylation with calcium mobilization and other functional readouts

  • Apply this method to heterogeneous B cell populations to identify distinct signaling signatures

• Time-resolved proximity labeling:

  • Use CD19-APEX2 fusion proteins to map the CD19 interactome changes over time

  • Identify proteins that associate with CD19 specifically after Y531 phosphorylation

  • Map the sequence of recruitment events following BCR stimulation

• Integrated data analysis approaches:

  • Combine phosphoproteomic data with transcriptomic profiling to identify feedback mechanisms

  • Use computational modeling to predict pathway behaviors based on phosphorylation patterns

  • Apply principal component analysis to identify key patterns in complex phosphorylation datasets

• Technical implementation:

  • Standardize stimulation protocols (e.g., anti-IgM F(ab')2 fragments for BCR crosslinking)

  • Include multiple timepoints to capture rapid phosphorylation kinetics (10 seconds to 2 hours)

  • Normalize phosphorylation data to total CD19 levels to account for expression differences

What are common challenges in detecting CD19 Y531 phosphorylation and their solutions?

Researchers frequently encounter several challenges when studying CD19 Y531 phosphorylation:

When working with paraffin-embedded tissue samples, the following protocol yields optimal results:

• Boil in sodium citrate buffer (pH6) for 15 minutes

• Block endogenous peroxidase with 3% hydrogen peroxide for 30 minutes

• Apply blocking buffer (normal goat serum) at 37°C for 20 minutes before antibody incubation

How can contradictory phospho-CD19 (Y531) data be reconciled in experimental settings?

When researchers encounter contradictory results regarding CD19 Y531 phosphorylation, systematic troubleshooting is essential:

What experimental design principles optimize phospho-CD19 (Y531) research outcomes?

Robust experimental design for studying CD19 Y531 phosphorylation should incorporate these key principles:

• Comprehensive controls:

  • Positive controls: B cells stimulated with anti-IgM for 2 minutes

  • Negative controls: CD19-deficient cells or phosphatase-treated samples

  • Technical controls: Isotype antibodies and secondary-only controls for immunostaining

• Temporal considerations:

  • Include multiple early timepoints (10s, 30s, 1min, 2min) to capture rapid phosphorylation kinetics

  • Extend to later timepoints (5min, 15min, 30min, 2h) to track signal resolution

  • Synchronize cell populations before stimulation for more uniform responses

• Multiparameter analysis:

  • Monitor multiple phosphorylation sites simultaneously (CD19 Y531, Syk Y525/526, BLNK Y119)

  • Correlate phosphorylation with functional outcomes (calcium flux, proliferation)

  • Use flow cytometry to analyze phosphorylation at the single-cell level

• Physiological relevance:

  • Compare BCR and TLR9 stimulation to understand convergent signaling

  • Use primary human B cells whenever possible rather than cell lines alone

  • Consider three-dimensional culture systems that better mimic physiological conditions

How might single-cell technologies advance our understanding of CD19 Y531 phosphorylation heterogeneity?

Emerging single-cell technologies offer unprecedented opportunities to understand heterogeneity in CD19 Y531 phosphorylation:

• Single-cell phosphoproteomics:

  • Mass cytometry (CyTOF) can simultaneously measure multiple phosphorylation sites at single-cell resolution

  • This approach reveals subpopulations with distinct CD19 Y531 phosphorylation patterns

  • Correlation with cell surface markers helps identify B cell subsets with unique signaling properties

• Spatial phosphoprotein mapping:

  • Imaging mass cytometry allows visualization of phospho-CD19 Y531 distribution within tissue microenvironments

  • Multiplex immunofluorescence provides spatial context for phosphorylation events

  • These approaches reveal how tissue niches influence CD19 signaling in vivo

• Live-cell phosphorylation sensors:

  • FRET-based biosensors can monitor CD19 Y531 phosphorylation dynamics in living cells

  • Optogenetic tools allow precise temporal control of CD19 activation

  • These approaches reveal real-time phosphorylation kinetics without cell fixation artifacts

• Single-cell multi-omics:

  • Integrated analysis of phosphorylation status with transcriptomics and epigenomics

  • This reveals how CD19A Y531 phosphorylation influences gene expression programs

  • Computational modeling predicts how signaling heterogeneity translates to functional diversity

What therapeutic implications does CD19 Y531 phosphorylation research have?

Research on CD19 Y531 phosphorylation has significant therapeutic implications:

• Targeted therapy development:

  • Small molecules targeting proteins that interact with phosphorylated CD19 Y531

  • Peptide mimetics that disrupt specific phosphorylation-dependent protein interactions

  • Degraders (PROTACs) targeting phosphorylated CD19 complexes

• Biomarker applications:

  • CD19 Y531 phosphorylation levels as predictive biomarkers for response to B cell-directed therapies

  • Monitoring phosphorylation dynamics to assess treatment efficacy

  • Using phospho-flow cytometry for patient stratification in clinical trials

• CAR-T cell optimization:

  • Engineering CD19 CAR-T cells that recognize specific phosphorylation states

  • Targeting signaling pathways downstream of CD19 Y531 phosphorylation

  • Developing combination therapies that modulate CD19 phosphorylation

• Immunodeficiency treatment approaches:

  • Gene therapy strategies to restore normal CD19 Y531 phosphorylation in CVID patients

  • Small molecules that can bypass CD19 phosphorylation defects to activate downstream pathways

  • Biologics that mimic phosphorylation-dependent signaling events

How do interferons and other cytokines modulate CD19 Y531 phosphorylation?

The interplay between cytokines and CD19 Y531 phosphorylation represents an important area for future research:

• Interferon effects:

  • IFITM3 functions as a PIP3-scaffold to amplify PI3K signaling in B cells

  • This scaffolding requires the CD19-Y531 PI3K-activation motif

  • Type I interferons may modulate CD19 phosphorylation through this mechanism

• Cytokine integration:

  • Investigating how IL-4, IL-21, and BAFF influence CD19 Y531 phosphorylation

  • Determining whether cytokines modify the kinetics or magnitude of phosphorylation

  • Exploring cross-talk between cytokine receptors and CD19 signaling complexes

• Methodological approaches:

  • Time-course experiments combining cytokine pre-treatment with BCR stimulation

  • Phospho-flow cytometry to quantify effects at single-cell resolution

  • Proximity labeling to map changes in CD19 interactome following cytokine exposure

• Therapeutic implications:

  • Exploring combination therapies targeting both cytokine signaling and CD19 pathways

  • Developing strategies to overcome cytokine-mediated resistance to B cell-directed therapies

  • Using cytokines to selectively modulate CD19 phosphorylation in therapeutic contexts